Last reviewed · How we verify
Symbicort Turbohaler
Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).
Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). Used for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.
At a glance
| Generic name | Symbicort Turbohaler |
|---|---|
| Also known as | Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder, Reference product |
| Sponsor | Pearl Therapeutics, Inc. |
| Drug class | Corticosteroid and long-acting beta2-adrenergic receptor agonist combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes bronchial muscles, making it easier to breathe. This combination allows for effective control of symptoms in patients with asthma and COPD.
Approved indications
- Maintenance and relief of asthma symptoms
- Maintenance treatment of COPD
Common side effects
- Oral candidiasis
- Headache
- Cough
Key clinical trials
- An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (PHASE4)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (PHASE3)
- Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER® (PHASE3)
- A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers (PHASE1)
- Clinical Study to Evaluate Z7200 Pharmacokinetics Profile (PHASE1)
- Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients (PHASE2)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort Turbohaler CI brief — competitive landscape report
- Symbicort Turbohaler updates RSS · CI watch RSS
- Pearl Therapeutics, Inc. portfolio CI